Adelaide Evans, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-389-6270 |
Dr. Jonathan David Pierce, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-381-7150 |
Phyllis M Chen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Emergency Dept., Whidden Memorial Hospital, 103 Garland Street, Everett, MA 02149 Phone: 617-389-6270 |
Brian P Lyngaas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-389-6270 |
Dr. Richard Michael Louissaint, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-665-1430 |
Wilfred P Hodgdon, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Emer Dept Widden Hosp, 103 Garland Street, Everett, MA 02149 Phone: 617-381-7150 |
Thomas Pedro Goldberger, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, C/o Whidden Mem Hospital, Everett, MA 02149 Phone: 617-381-7150 |
Dr. Julie A Zeller, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-381-7150 |
Gary Blair, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 103 Garland St, Everett, MA 02149 Phone: 617-665-1000 |
News Archive
A wide variety of experiments have shown that nanoscale quantum dots have the potential to detect early-stage cancer and even monitor the progress of anticancer therapies.
Protein Metrics, Inc., a leading provider of software for rapid and thorough protein characterization, today announced the release of Byologic. Byologic software enables easy and convenient identification and quantification of sequence variants, protein modifications, and degradants down to trace concentrations.
Some question if members of Congress and their staffs should continue getting a federal employer contribution toward the cost of buying insurance on the health law exchange.
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.
› Verified 1 days ago